Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Michael Weichenthal
Forschungsportal der TU Dresden
Background: Randomised trials recently showed that sequencing of first-line (1 L) immune checkpoint inhibitor (ICI) and second-line (2 L) BRAF-MEK-inhibitor (BRAF/MEKi) combination therapy provides better clinical outcomes in BRAFV600-mutated, irresectable/metastatic melanoma than the inverse sequence. However, efficacy benchmark data for 2 L BRAF/MEKi are limited as the combination was developed for 1 L use, lacking estimates for the impact of prior ICI.
Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study
1L first-line 2L+ second- or later-line ABC Anti–PD-1 Brain Collaboration ADOReg German skin cancer registry AE adverse event BOR best overall response CI confidence interval CNS central nervous system CR complete response D/C discontinuation DCR disease control rate deCOG German Dermatologic Cooperative Oncology Group ECOG PS Eastern Cooperative Oncology Group performance status eCRF electronic case report form EORTC QLQ-C30 European Organization for Research and Treatment of Cancer Quality...
Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study
aSkin Cancer Center Kiel, University Hospital Schleswig-Holstein, Kiel, Germany bNational Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark cDepartment of Dermatology, University Hospital Zurich, Zurich, Switzerland dSkin Cancer and Melanoma Center at Davidoff Cancer Center, Rabin Medical Center, Israel eOncodermatology Department, National Oncology Center, Sofia, Bulgaria fDepartment of Dermatology, Faculty of Medicine,...
Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Rare haematologic and neurologic drug reactions from immune checkpoint inhibition in a responding patient with metastatic anorectal mucosal melanoma
Immune checkpoint inhibitors (ICIs) blocking engagement with the cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) or the programmed death 1 (PD-1) receptors have emerged to dramatically improve the treatment outcome of various advanced cancer types. In melanoma, the combination of nivolumab (anti-PD-1) with ipilimumab (anti-CTLA-4) has demonstrated significantly improved long-term survival [ [1] Larkin J. Chiarion-Sileni V. Gonzalez R. Grob J.J. Rutkowski P. Lao C.D. et al.
Role of Eosinophils in Angiolymphoid Hyperplasia With Eosinophilia
Angiolymphoid hyperplasia with eosinophilia (ALHE) is a rare skin disease that manifests with erythematous-violaceus nodules that are mostly located on the head and neck.1,2 It is characterized by proliferating blood vessels with a lymphoid infiltration interspersed with eosinophils.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Michael
Contact Michael, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack